Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

JCO precision oncology·2026
Same author

Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials.

Cancer medicine·2026
Same author

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cancer chemo-immunotherapy: time will tell.

Cancer immunology research·2026
Same author

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

Journal for immunotherapy of cancer·2026
Same author

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: May 3, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Targeted therapy in sarcoma: should we be lumpers or splitters?

Richard F Riedel1, Robert G Maki1, Andrew J Wagner1

  • 1From the Duke Cancer Institute, Duke University Medical Center, Durham, NC; Mount Sinai School of Medicine, New York, NY; Dana Farber Cancer Institute, Boston, MA.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|January 24, 2014
PubMed
Summary

Targeted therapies show promise for sarcomas, including specific subtypes. Research highlights data supporting targeted therapy in both unselected and selected sarcoma patient populations for improved outcomes.

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

8.5K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

13.9K

Related Experiment Videos

Last Updated: May 3, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

8.5K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

13.9K

Area of Science:

  • Oncology
  • Medical Research

Background:

  • KIT's role in gastrointestinal stromal tumors (GIST) and imatinib's success spurred targeted therapy research in sarcomas.
  • Sarcoma subtypes are rare, leading to clinical trials with unselected patient populations, complicating efficacy interpretation.
  • Interpreting targeted therapy trials in sarcomas is challenging due to small patient numbers per subtype and lack of correlative data.

Purpose of the Study:

  • To review evidence supporting targeted therapy in sarcoma treatment.
  • To discuss the application of targeted therapies in both unselected and selected sarcoma patient groups.

Main Methods:

  • Literature review of preclinical and clinical data.
  • Analysis of clinical trial strategies in sarcoma research.
  • Evaluation of targeted therapy approaches in various sarcoma subtypes.

Main Results:

  • Preclinical and clinical observations suggest targeted therapies are effective in specific sarcoma subtypes.
  • Data supports the use of targeted therapies in both broad and narrowly defined sarcoma patient populations.
  • Challenges in interpreting trial results for targeted therapies in rare sarcoma subtypes were noted.

Conclusions:

  • Targeted therapy is a viable strategy for sarcoma treatment, with potential benefits in selected subtypes.
  • Further research is needed to optimize targeted therapy selection and trial design for rare sarcomas.
  • Understanding sarcoma heterogeneity is key to successful targeted treatment strategies.